Key Clinical Data (Authoritative Research) - Obesity: 28.7% average weight loss over 68 weeks (TRIUMPH-4 Study) - 12 mg dose: 17.5% weight loss (24w), 24.2% (48w) - Diabetes: Improves glycemic control, safety similar to GLP-1 RAs Molecular Design Highlights - GIP peptide backbone (39 amino acids), ~6-day half-life, good adherence - Special modifications: enhanced stability, long-acting, suitable for long-term use Research Focus Populations - Adults with type 2 diabetes (with diet/exercise) - Adults with obesity/overweight + weight-related comorbidities Industry Significance From single/dual-target to triple agonist, Retatrutide leads metabolic drug research, redefining diabetes/obesity research paradigms
Our work at Pepsynth Labs focuses on custom peptide manufacturing and high-purity peptide compounds for technical applications
Most peptides work by signaling your bodys own hormone production rather than introducing synthetic hormones directly which is one of the reasons they tend to have a more favorable safety profile
Based on the results of the study, Dr
Individuals taking chemotherapy drugs, blood thinners, or immunosuppressive medications should consult healthcare providers before beginning supplementation
